Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/564,224external-prioritypatent/US4518584A/en
Application filed by Chiron CorporationfiledCriticalChiron Corporation
Publication of BG60657B2publicationCriticalpatent/BG60657B2/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Мутеините на биологически активни протеини като ifvи il-2, в които цистеиновите остатъци не са съществени за биологическата активност, са отстранени или заместени с други аминокиселини за елиминиране на местата за интермолекулярно образуване на дисулфидни мостове. Тези мутеини се получават чрез бактериално изразяване на мутантни гени, кодиращи мутеини, които са синтетизирани от гените за родителските протеини чрез олигонуклеотидно насочена мутагеназа. 10 претенции, 17 фигуриThe muteins of biologically active proteins such as ifvi and il-2, in which cysteine residues are not essential for biological activity, have been removed or replaced with other amino acids to eliminate sites for intermolecular disulfide bridge formation. These muteins are produced by bacterial expression of mutant genes encoding muteins that are synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenase. 10 claims, 17 figures
OXIDATION-RESISTANT IL-2 MUTEINS AND THEIR PRODUCTION, THEIR COMPOSITIONS CONTAINING THE SAME, SUCH MUTEINE ENCODING DNA SEQUENCES AND EXPRESSION VECTORS AND CORRESPONDING TRANSFORMED CELLS.